Stefan Doboczky will leave the chairmanship of Hovione's Board of Directors to assume the role of chief executive officer (CEO) of the company. The change will take effect from April 1, 2027, as announced by the group.
This transition represents a significant change in Hovione's leadership structure, which until now had Doboczky only in the role of chairman of the company's supervisory body.
Hovione is a company in the pharmaceutical sector that operates in the area of development and production of active ingredients and dosage forms. The announcement was made by the group without providing further details about the reasons for the change or about who will replace Doboczky as chairman of the Board of Directors.



